The FDA has approved a drug developed by Cytokinetics for its intended use as a treatment.
3 reports, 2 independent
Updated Jun 29
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA has approved a drug developed by Cytokinetics for its intended use as a treatment.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Product Myqorzo received FDA approval.Sub-event
Cytokinetics drug moves toward global commercial rollout following regulatory approvals.1 source
FDA approves Cytokinetics' drug as a treatment.1 source
Keep exploring
The entities involved
- FDA
-
Cytokinetics
company in South San Francisco, United States
Related events
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- FDA approved a drug based on UVA research led by Xuemei Huang.
- InflaRx is seeking discussions with the FDA and collaborating with Staidson BioPharmaceuticals on clinical trials.
- Johnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.
- Discussion on the limits of pharmacotherapy and the role of FDA approvals.